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MRSA is a dominant hospital pathogen because of its increasing incidence, the cost of treatment, 
antibiotic resistance, limited antimicrobial armamentarium, and associated increased mortality.  
Determining risk factors for MRSA acquisition in hospital settings has important public health relevance 
for defining targets for infection control, reduction in mortality from hospital-acquired infections, and 
decreasing hospitalization costs.  A retrospective matched case-control study was initiated to determine 
patient-associated risk factors for MRSA acquisition at the Presbyterian University Hospital.   It was 
hypothesized that risk factors for MRSA acquisition could be identified and used to enhance or tailor 
infection control strategies.  Cases and two matched controls were selected among patients admitted to 
high risk units where MRSA screening was routinely done from January 2001 to December 2008. Cases 
were subjects who acquired MRSA during hospitalization. Variables collected were potential patient-
associated risk factors associated with MRSA acquisition among cases versus controls.  The odds of 
exposure to potential risk factors for MRSA acquisition were compared between cases and controls, using 
matched univariate conditional logistic regression. A single multivariate conditional logistic regression 
model identifying patient-specific risk factors significantly associated with MRSA acquisition was 
generated.   
The final model included 15 independently significant variables. Seven factors were positively 
associated with MRSA acquisition: primary diagnosis of respiratory disease, digestive tract disease, or 
injury/trauma, any diagnosis of pneumonia, cerebrovascular/peripheral vascular disease, intracranial 
ventricular shunt procedure, and a high risk unit stay prior to index culture. Eight variables were 
protective and included two beta lactam antibiotic classes (penicillin and cephalosporin), rifamycin, 
daptomycin/linezolid, proton pump inhibitors, history of transplant, extracorporeal membrane 
oxygenation, and intravascular stenting/catheterization.  As 3 of the 7 factors positively associated with 
MRSA acquisition were conditions present on admission, they were not modifiable. Of the remaining 4, 
pneumonia could potentially be reduced by maintaining high compliance with pneumococcal vaccine. 
Admission to a high risk unit in itself is not modifiable. Although ventricular shunting was a factor, the 
lack of association with many common bedside or interventional procedures performed in these high risk 
areas argues for intensified environmental control and strict sterile technique for all procedures performed 
on patients.  
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1.0  BACKGROUND 
Methicillin resistant Staphylococcus aureus (MRSA) is an important pathogen that continues to cause 
substantial morbidity and mortality among patients and to beleaguer infection control preventionists since 
it emerged in the healthcare setting decades ago [1].   It causes a broad spectrum of community-associated 
and healthcare-associated infections, including pyogenic infections of skin and soft tissues, pneumonia, 
and bacteremia, and is a leading cause of hospital-acquired infections in the United States and worldwide 
[2-4]. MRSA is an important public health problem because of its increasing incidence, the cost of 
treating MRSA infections, its resistance to antibiotics, the limited antimicrobial armamentarium directed 
against MRSA, and associated increased mortality [5-9]. 
MRSA colonization increases infection risk and MRSA colonized individuals can be reservoirs 
for transmission in healthcare facilities [10-11].  Collective risk factors for MRSA acquisition previously 
identified include MRSA colonization pressure (i.e. the proportion of other patients colonized), care 
workload, and antibiotic pressure (defined daily dose per 1000 patient days) [12-16].  Individual patient 
risk factors for MRSA acquisition or colonization previously identified include length of hospital stay; the 
presence of open wounds or skin ulcers; admission to a trauma unit; the presence of a tracheostomy or use 
of nasoenteric feeding tubes; a high Omega Score (a composite score of commonly performed hospital 
procedures); a high Acute Physiology and Chronic Health Evaluation II (APACHE II) score or new 
Simplified Acute Physiology Score (SAPS II); exposure to a roommate with MRSA; dependency in 
feeding, continence, and ambulation; and fluoroquinolone use [15, 17-24].  Some of the studies that 
identified these risk factors involved only specific settings or populations, such as surgical intensive care 
units (ICUs) or transplant populations, and were not always applicable to our setting. Most had small 
numbers of patients known to recently acquire MRSA (converters).  Moreover, not all of the reporting 
facilities actively surveyed patients for MRSA, which limits the ability to accurately assess colonization 
status and /or time of MRSA acquisition.  
Surveillance data at the University of Pittsburgh Medical Center (UPMC) Presbyterian University 
Hospital from 2005 to 2008 revealed an average MRSA hospital acquisition rate of less than 2%.  
Although this rate is relatively low, the challenge facing hospitals today is to get rates as close to zero as 
possible.  With this in mind, a retrospective study with a matched case-control study design was initiated 
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to determine patient-associated risk factors for acquisition of MRSA at our hospital despite current 
infection control efforts.   It was hypothesized that MRSA acquisition could decrease if modifiable risk 
factors were identified.  The study was approved by the UPMC Total Quality Council as a quality 
improvement project. 
With more than 7 years of culture data from our MRSA active surveillance program and a rich 
database of electronic health records, this study would have comparatively greater power to define 
patient-associated risk factors for MRSA acquisition than previous studies.  Determining risk factors for 
MRSA acquisition in hospital settings has important public health relevance for reduction in mortality 
from hospital-acquired infections and decreasing costs of hospitalization. Identifying these risk factors 
could help determine new strategies for infection control interventions in our hospital as well as other 
similar hospital settings.  For example, if specific medical or surgical procedures or specific 
subpopulations could be identified, well designed tailored enhanced infection control strategies could be 
applied to reduce the risk of MRSA acquisition. 
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2.0  METHODS 
2.1 SETTING AND POPULATION 
The UPMC Presbyterian University Hospital (PUH), a 766-bed tertiary care teaching facility with 156 
ICU beds, utilizes an MRSA prevention bundle that has been implemented in phases since 2001.  Patients 
with a hospital stay in high risk areas and those admitted from outside high risk facilities (long-term care, 
other health-care facilities) undergo active surveillance testing (AST) for MRSA nasal colonization.  High 
risk areas are those units historically identified by the UPMC Infection Control Department as having 
patient populations with higher MRSA hospital-acquired infection rates. Patients admitted to high risk 
areas are cultured on admission, weekly, and upon discharge from the high-risk area while those admitted 
from high risk facilities are screened on hospital admission.  AST was first implemented in the medical 
ICU. As additional high risk areas were identified, MRSA AST was commenced over time.  High risk 
areas at PUH now include all ICUs (medical, surgical, cardiothoracic, neurosurgical/neurology, solid 
organ transplant, coronary care, and trauma), the orthopedic unit, and medical step down patient care 
areas.    
2.2 ROUTINE MICROBIOLOGY METHODS 
Both anterior nares are swabbed with sterile cotton-tipped culturettes (Becton Dickinson (BD) Diagnostic 
Systems, Franklin Lakes, NJ).  Specimens are plated on BBL CHROMagar MRSA media (BD) and 
incubated overnight.  Culture growth of pink or mauve colonies is considered MRSA positive.  Blood and 
body fluid cultures are incubated in the automated BD BACTEC Instrumented Blood Culture System 
(BD) and clinical specimens from various body sites are planted and incubated on BBL trypticase soy 
agar with 5% sheep blood (BD).  Coagulase-positive staphylococci are tested for oxacillin resistance by 
plating and incubating isolates on a BBL Oxacillin Screen Agar plate (BD) and the Kirby Bauer disk 
diffusion method. 
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2.3 DEFINITIONS AND INFECTION CONTROL PRACTICES 
Patients are considered to have pre-existing MRSA if they are known or found to be MRSA colonized or 
infected within 2 days of hospital admission.  MRSA hospital acquisition is said to have occurred and a 
patient considered to be a converter if found to be MRSA colonized or infected 3 or more days after 
admission to the hospital or high risk area.  Patients known or determined to be colonized or infected with 
MRSA are placed in droplet contact precautions, either in a private room or cohorted with other MRSA 
colonized or infected patients.   
2.4 SELECTION OF CASES AND CONTROLS  
Cases and controls were selected using de-identified datasets from the UPMC electronic health record 
database, using an algorithm that was programmed based on inclusion and exclusion criteria.   Patients 
admitted to high risk units where AST was being performed and who had nasal screening cultures for 
MRSA or clinical cultures that were positive for MRSA from January 2001 to December 2008 were 
identified as potential subjects.  Cases were defined as MRSA converters who fulfilled the following 
inclusion criteria: presence of at least one prior negative MRSA nasal surveillance culture during the 
hospital admission and a subsequent positive MRSA culture, whether nasal or a clinical culture from any 
body site, occurring 3 or more days after hospital admission.  Potential cases were excluded if they had a 
concurrent MRSA positive culture on the same day as their negative MRSA nasal surveillance culture and 
if they had a prior documented MRSA history or culture.  Inclusion criteria for controls were the presence 
of at least one negative nasal surveillance culture taken 3 or more days after hospital admission.  Subjects 
were excluded from being a control if they had a concurrent MRSA positive culture, a prior documented 
MRSA history or culture, or a subsequent positive MRSA culture within the study period.  Two unique 
controls for each case were chosen when possible,  individually matched to the case by (1) the date the 
index negative culture was received at the laboratory, which had to be within 7 days of the case’s index 
positive culture,  (2) patient location in the same or the closest similar hospital unit at the time of culture 
(i.e., a medical ICU (MICU) patient was matched to a control in an adjacent MICU and would not be 
matched with a patient in a surgical ICU), and (3) a minimum duration of stay, i.e. the control should 
have stayed in the hospital at least the same number of days between the case’s last negative culture and 
index MRSA culture (Figure 1).  Index culture refers to the first positive culture for the cases and the 
corresponding negative culture for the controls, and culture dates were considered the date the culture 
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specimen was received at the microbiology laboratory.  For the cases, prior negative cultures could be 
taken at any time and in any unit location during the hospitalization, and for both cases and controls, the 
index culture could be received at any time during the admission to the high-risk unit, as long as it was 3 
or more days from the hospital admit date.  The hospitalization during which the cases and controls were 
identified was considered the index admission.  Cases for which a matching control could not be 
identified were excluded from the analyses. 
 
 
 
 Note: Arrows represent duration of hospital stay and (–) and 
(+) represent negative nasal surveillance cultures and any 
positive MRSA culture respectively.  
 
 
 
 
Figure 1. Method for Matching Cases and Controls Utilizing a Minimum Duration of Stay 
2.5 SUBSET ANALYSIS   
A subset of cases whose negative nasal surveillance cultures and subsequent MRSA positive cultures 
were obtained during a contiguous high risk unit stay and whose positive cultures were obtained 3 or 
more days after admission to a high risk unit was analyzed, along with their matched controls.   Another 
subset of cases that were defined as converters based on a subsequent positive MRSA nasal surveillance 
culture, excluding those cases identified by subsequent MRSA positive clinical cultures from other body 
sites, was also analyzed, along with their matched controls.  These subset analyses were performed to 
confirm the results of the larger dataset and to reduce the chance of detection bias in determining 
conversion from a negative to a positive MRSA status.   
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2.6 DEFINITIONS AND COLLECTION OF DATA 
Variables collected were potential patient-associated risk factors associated with the acquisition of 
MRSA.  All data were obtained from the UPMC electronic health record database, guided by a data 
collection tool.  No subject interviews were conducted.    Datasets were de-identified by an honest broker 
and data collectors were blinded to the case/control status of the subjects.  Demographic data collected 
included age, sex, and race.  Information regarding hospitalization were collected, and included  
admission from a long-term care facility, status of admission (elective, urgent, or emergent), admitting 
service (medical, surgical or other), unit locations (defined as high risk or non-high risk by the Infection 
Control Department), the primary diagnosis which kept the patient in the hospital, duration of entire 
hospital stay, duration of hospital stay until the date of the index culture, other UPMC hospitalizations in 
the past 6 months, and whether alive or deceased at discharge.  For subjects who had a length of stay in 
either a high risk or non-high risk unit prior to the index culture, cumulative duration of stay in a high or 
non-high risk unit was calculated until the date of the index culture.   
Comorbid illnesses and conditions present on admission were noted, based on combined data 
from ICD9 diagnostic and procedure codes documented during index and prior admissions, ICD9 main 
diagnostic categories, and hospital charges [25-27].  Diabetes mellitus, chronic kidney disease, cirrhosis, 
malignancy, chronic obstructive pulmonary disease (COPD), HIV/AIDS, and congestive heart failure 
(CHF) diagnoses in the current or any prior admission were considered.  A diagnosis of C. difficile 
associated disease and any substance abuse or dependence or the presence of devices such as a 
tracheostomy, ventricular shunt, gastrointestinal stoma, subcutaneously implanted intravenous port, 
intracardiac defibrillator, or pacemaker were considered in any admission within the past 6 months.  
Other diagnoses such as myocardial infarction, pneumonia, sepsis, infection, acute renal failure, skin ulcer 
(venous stasis or decubitus), and cerebrovascular or peripheral vascular disease were considered only if 
they were noted during the index admission. A history of transplant was classified under the variable 
immunosuppression if the subject had a solid organ transplant during the current or any prior admission 
or if bone marrow transplant was performed during an admission within 1 year of the index culture.  
Significant steroid use was defined as documented use of systemic steroids more than or equivalent to 40 
mg of prednisone for 1 week in the past 6 months.  Other causes for immunosuppression included severe 
primary immunodeficiencies and radiotherapy or receipt of chemotherapeutic agents or other 
immunosuppressive drugs within the past 6 months.  The Charlson Comorbidity Index of each subject 
was calculated based on ICD9 codes during the index admission and adjusted for each decade of age 
above 50 [28].  
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Information was obtained from Infection Control Department records on institution of contact 
isolation for other multi-drug resistant organisms (MDROs) such as vancomycin resistant enterococci 
(VRE), Clostridium difficile, and multi-drug resistant Acinetobacter baumanii during the subject’s index 
admission, prior to the index culture.  Culture data on the isolation of other MDROs in the past 6 months 
prior to the index culture was also obtained from the electronic health record.  Complete data for 
generating an established acute physiologic score were not available so laboratory values typically used 
for severity scores were obtained from the electronic health record to provide a partial picture of severity 
of illness.  The laboratory values that were most abnormal within 7 days of the index culture were used 
and sorted into simplified categories based on cut-off values correlated with poor prognosis or higher 
mortality used in APACHE II and SAPS III scoring systems and prior studies, when applicable [29-31].  
ICD9 codes and hospital charges were also utilized to determine procedures that were performed in the 30 
days prior to the index culture, such as mechanical ventilation, Foley catheterization, dialysis, and 
surgeries.  Surgery was considered major based on a classification system used by the Centers for 
Medicare & Medicaid Services (CMS) [32].   Charge codes were utilized to determine oral and 
intravenous antibiotic or antifungal, and topical mupirocin use in the past 6 months, H2 blocker and 
proton pump inhibitor (PPI) use in the past 30 days, and vasopressor use in the past 7 days, prior to the 
index culture.  
2.7 STATISTICAL METHODS   
The frequency of dichotomous variables among the cases and controls were described as number and 
percentage of the total number while continuous variables were described using mean and standard 
deviation.  The odds of exposure to potential risk factors for acquisition of MRSA were compared 
between the cases and controls, using univariate conditional logistic regression for both binary and 
continuous data, conditioning on the matched sets of subjects.  Matched odds ratios (mOR) for categorical 
variables reflect the odds of exposure to a variable for the cases versus the controls while OR for 
continuous variables reflect the increase in the OR for every unit increase in the variable. Race, admitting 
service, primary diagnosis, and discharge disposition were analyzed as categorical variables; the p values 
indicate the significance of the difference of the distribution of all categories between cases and controls 
while mORs reflect the odds of one exposure category compared to a designated reference category.  A 
single multivariate conditional logistic regression model to identify patient-specific risk factors that are 
significantly associated with MRSA acquisition was generated, using forward and backward stepwise 
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regression methods on variables that had a p value of < 0.10 on univariate analysis.  A cut-off p value of  
< 0.05 was used for the final model.  Selected biologically plausible interactions between covariates that 
were found significant on multivariate analysis were tested individually and interaction terms were added 
to the combined multivariate main effect logistic regression model if significant.  The same statistical 
methods were applied in analyzing the subsets.  Sample size calculations using the Pearson chi-square test 
for 2 proportions indicated that 235 cases and 470 controls were needed to achieve 90% power to detect 
an OR of 2.0 with 2-sided α of .05 .  All analyses were performed using SAS 9.2 software. 
  8
  9
3.0  RESULTS 
3.1 UNIVARIATE ANALYSIS 
A total of 475 cases were identified.  Of these, 19 cases could not be matched to controls and were 
excluded from analyses.  Four hundred fifty six cases and 880 matched controls comprised the main set of 
subjects analyzed. Some cases had only 1 control since a second eligible control based on matching 
criteria could not be identified.  A subset of 287 cases whose index culture was a nasal surveillance 
culture with 553 matched controls and a second subset of 362 cases whose initial negative and subsequent 
positive index cultures were obtained during their high risk unit stay with 607 matched controls were also 
analyzed.   
Overall, 27 variables were found to be significant in the univariate analysis. Table 1 shows the 
demographic and admission characteristics of the main set of cases and controls. On univariate analysis, 
admission from a long-term facility and stay in a high risk unit prior to index culture was significantly 
associated with MRSA acquisition whereas stay in a non-high risk unit prior to index culture was 
protective as was prior acquisition of VRE.   Cases and controls did not differ significantly in age, sex, 
race, urgency of admission, admitting service, recent hospitalization at UPMC, substance abuse or 
dependence, age-adjusted Charlson Comorbidity Index, total abnormal or extreme laboratory values, 
isolation of other MDROs, contact isolation for another MDRO during hospitalization, or discharge 
disposition.  
Table 1. Univariate Analysis of Demographic and Admission Characteristics 
Variable                                                                           Odds Ratio 
 (95% CIs) 
No. (%) of Cases 
(n=456) 
or Mean ± SD 
No. (%) of Controls 
(n=880) 
or Mean ± SD 
p value 
Age 1.00 (1.00, 1.01) 60.2 ± 17.5 59.1 ± 16.5 .27 
Male Sex 0.95 (0.75, 1.20) 252 (55.3) 492 (55.9) .68 
Race - - - .99 
          White 1.00 335 (73.5) 649 (73.8) - 
           Black 1.03 (0.70,  1.53) 42 (9.2) 79 (9.0) - 
          Other or Unknown 1.00 (0.73,  1.37) 79 (17.3) 152 (17.3) - 
Emergent or Urgent Admission 1.08 (0.74, 1.57) 406 (89.0) 779 (88.5) .68 
Admission from Long-Term Care Facility 1.59 (1.04, 2.44) 42 (9.2) 51 (5.8) .03 
Admitting Service - - - .45 
          Medical 1.00 266 (60.2) 530 (58.3) - 
          Surgical 1.15 (0.87, 1.53) 183 (40.1) 332 (37.7) - 
          Other  0.71 (0.28, 1.82) 7 (1.5) 18 (2.0) - 
Length of stay (LOS)  (Days) 1.00 (1.00, 1.00) 42.0 ± 53.7 44.1 ± 40.1 .43 
          LOS Prior to Index Culture (Days) 1.00 (1.00, 1.00) 20.9 ± 45.9 20.8 ± 25.8 .99 
High Risk Unit Stay Prior to Index Culture 6.4 (2.28, 17.95) 452 (99.1) 834 (94.8) .0004 
          LOS in High Risk Unit (Days) 1.00 (1.00, 1.00) 16.8 ± 44.5 15.8 ± 20.0 .67 
Non-High Risk Unit Stay Prior to Index Culture  0.64 (0.50, 0.81) 198 (43.4) 475 (54.0) .0002 
          LOS in Non-High Risk Unit (Days) 0.99 (0.97, 1.00) 9.6 ± 11.8 10.7 ± 15.2 .14 
Other UPMC Hospitalization in Past 6 Months 0.87 (0.64, 1.19) 68 (14.9) 144 (16.4) .39 
Substance Abuse or Dependence     
          Alcohol 0.84 (0.57, 1.23) 42 (9.2) 95 (10.8) .37 
          Drug 1.13 (0.67, 1.93) 23 (5.0) 41 (4.7) .65 
          Tobacco 0.89 (0.58, 1.37) 35 (7.7) 73 (8.3) .59 
Primary Diagnosis - - - .06 
          Circulatory Disease 1.00 89 (19.6) 214 (24.3) - 
          Respiratory Disease 1.71 (1.16, 2.53) 103 (22.6) 152 (17.3) - 
          Digestive Tract Disease 1.39 (0.89, 2.20) 49 (10.8) 87 (9.9) - 
          Injury or Trauma 1.40 (0.95, 2.07) 101 (22.2) 182 (20.7) - 
          Other Diagnosisa 1.16 (0.80, 1.67) 113 (24.8) 245 (27.8) - 
 
aIncludes diseases classified under hematologv/oncology, infectious diseases, obstetrics/gynecology, rheumatology, dermatology, 
endocrinology, neurology, genitourinary, and psychiatry 
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Table 1 continued. 
Variable     Odds Ratio 
                                                                                         (95% CIs) 
No. (%) of Cases 
(n=456) 
or Mean ± SD 
No. (%) of Controls 
(n=880) 
or Mean ± SD 
p value 
Age-Adjusted Charlson Comorbidity Index 0.97 (0.94, 1.01) 3.8 ± 2.9 4.0 ± 3.0 .20 
Total Abnormal Laboratory Values 0.95 (0.88, 1.04) 4.5 ± 1.5 4.6 ± 1.5 .26 
          Albumin  < 3.5 g/dL 0.90 (0.71, 1.15) 275 (60.3) 549 (62.4) .41 
          Bilirubin ≥ 2 mg/dL 0.79 (0.57, 1.09) 77 (16.9) 173 (19.7) .14 
          CD4  < 200 cells/mm3 0.39 (0.10, 1.44) 5 (2.7) 16 (4.7) .16 
          Creatinine < 0.6 or ≥ 1.4 mg/dL 0.89 (0.68, 1.16) 335 (73.5) 664 (75.4) .40 
          Bicarbonate <22 or ≥ 32 meq/L 1.19 (0.94, 1.51) 265 (58.1) 475 (54.0) .15 
          Hematocrit < 30 or  ≥ 46 % 0.75 (0.44, 1.29) 430 (94.3) 841 (95.6) .30 
          Potassium <3.5 or ≥ 5.5 meq/L 0.91 (0.70, 1.19) 332 (72.8) 656 (74.6) .51 
          Sodium < 130 or ≥ 150 mmol/L 0.84 (0.66, 1.08) 135 (29.6) 286 (32.5) .19 
          WBC  < 3 or ≥ 15 X 109/L 0.90 (0.71, 1.14) 284 (62.3) 569 (64.7) .38 
 Other MDROs Isolated in the Past 6 Months     
          Vancomycin Resistant Enterococcus  0.75 (0.58, 0.97) 132 (29.0) 299 (34.0) .03 
          C. difficile 0.88 (0.56, 1.38) 32 (7.0) 67 (7.6) .57 
          Multi-drug Resistant A. baumanii 0.35 (0.09, 1.32) 3 (0.7) 14 (1.59) .12 
Prior Contact Isolation for Other MDROs  0.86 (0.67, 1.11) 155 (34.0) 322 (36.6) .25 
Discharge Disposition - - - .13 
          Alive 1.00 290 (63.6) 548 (62.3) - 
          Deceased 1.10 (0.83, 1.46) 113 (24.8) 196 (22.3) - 
          Unknown 0.73 (0.51, 1.04) 53 (11.6) 136 (15.4) - 
 
 
Comorbid illnesses and conditions present on admission for both groups, along with medical 
procedures performed in the past 30 days are presented in Table 2.  Univariate analysis identified 15 
significant risk factors. Four were associated with MRSA acquisition and included pneumonia, 
mechanical ventilation, intracranial ventricular shunt, and tube feeding. Eleven variables were identified 
as protective; three of these were comorbidities present on admission and included chronic kidney 
disease, immunosuppression, and solid organ transplant at any time (or at 12 or 6 months, data not 
shown) or bone marrow transplant within the past 12 months.  The remaining 8 protective variables were 
procedures performed in the past 30 days and included peritoneal dialysis or hemodialysis, extracorporeal 
membrane oxygenation (ECMO), intraaortic balloon pump (IABP) or ventricular assist device placement, 
intravascular stenting or cardiac catheterization, trans-esophageal echocardiography (TEE), 
gastrointestinal endoscopy, gastrointestinal surgery, and a higher total number of major surgeries.  
Notably, the presence of diabetes mellitus, C. difficile associated disease (CDAD), acute renal failure, 
skin ulcers, a tracheostomy, or a central venous catheter were not significant risk factors.    
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Table 2. Univariate Analysis of Comorbid Illnesses, Conditions Present During Admission, and Procedures 
Performed in the Past 30 Days 
 
Variable Odds Ratio 
 (95% CIs) 
No. (%) of Cases 
(n=456) 
 or Mean±/-SD 
No. (%) of Controls 
(n=880) 
 or Mean±/-SD 
p value 
Comorbidities and Conditions Present During Admission  
Myocardial Infarction 0.83 (0.63, 1.07) 114 (25.0)            253    (28.8)            .15 
Congestive Heart Failure 0.90 (0.69, 1.18) 139 (30.5) 284 (32.3) .44 
Cerebrovascular or Peripheral Vascular Disease 1.27 (0.96, 1.69) 121 (26.5) 203 (23.0) .09 
Diabetes Mellitus 0.92 (0.72, 1.18) 163 (35.8) 331 (37.6) .52 
Chronic Obstructive Pulmonary Disease 1.10 (0.87, 1.40) 174 (38.2) 312 (35.4) .41 
Sepsis 1.00 (0.78, 1.28) 192 (42.1) 369 (41.9) .98 
Pneumonia  1.60 (1.26, 2.03) 271 (59.4) 429 (48.8) .0001 
Any Infection 1.11 (0.81, 1.54)         384 (84.2)            729 (82.8)   .51 
C. difficile Associated Disease 0.83 (0.58, 1.19)           52 (11.4)            114 (13.0)                .31 
Chronic Kidney Disease 0.66 (0.48, 0.90) 68 (14.9) 180 (20.4) .01 
Acute Renal Failure 0.89 (0.67, 1.19) 88 (19.3) 186 (21.1) .44 
Cirrhosis 0.79 (0.48, 1.30) 24 (5.3) 55 (6.2) .35 
Venous Stasis or Decubitus Ulcer 1.34 (0.98, 1.85) 75 (16.4) 113 (12.8) .07 
Immunosuppression 0.75 (0.59, 0.96) 175 (38.4) 390 (44.3) .02 
         HIV/AIDS 1.15 (0.42, 3.17) 6 (1.3) 10 (1.1) .79 
         History of Transplant 0.44 (0.29, 0.69) 39 (8.6) 129 (14.7)  .0003 
         Significant Steroid Use 0.81 (0.62, 1.04) 141 (30.9) 309 (35.1) .10 
         Malignancy 0.81 (0.61, 1.07) 87 (19.1) 197 (22.4) .14 
         Othera 0.83 (0.46, 1.49) 18 (3.8) 40 (4.6) .53 
Intracardiac Pacemaker or Defibrillator 1.12 (0.74, 1.69) 39 (8.6) 68 (7.7) .60 
Tracheostomy 1.22 (0.96, 1.56) 188 (41.2) 327 (37.2) .11 
Gastrointestinal Stoma 0.83 (0.63, 1.11) 102 (22.4) 221 (25.1) .21 
Subcutaneous Intravenous Port 0.89 (0.45, 1.76) 207 (45.4) 401 (45.6) .73 
 
aIncludes immunosuppression from chemotherapy, radiotherapy, other immunosuppressive drugs, and other immunodeficiency 
syndromes 
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 Table 2 continued.
 
Variable Odds Ratio 
 (95% CIs) 
No. (%) of Cases 
(n=456) 
 or Mean±/-SD 
No. (%) of Controls 
(n=880) 
 or Mean±/-SD 
p value 
Procedures Performed in the Past 30 Days 
Mechanical Ventilation 1.89 (1.17, 3.05) 420 (92.1) 778 (88.4) .01 
BIPAP or CPAP Noninvasive Ventilationb 1.05 (0.80, 1.38) 100 (21.9) 187 (21.2) .72 
Bronchoscopy 1.08 (0.85, 1.37) 234 (51.3) 438 (49.8) .53 
Chest Tube Insertion 1.02 (0.72, 1.44) 68 (14.9) 132 (15.0) .93 
Thoracentesis 0.79 (0.53, 1.17) 40 (8.8) 95 (10.8) .24 
Central Venous Catheterization 0.77 (0.56, 1.05) 368 (80.7) 743 (84.3) .10 
          Peripherally Inserted Central Catheter  0.92 (0.72, 1.17) 273 (59.9) 546 (62.0) .48 
          Central Venous Pressure Monitor 0.70 (0.41, 1.19) 23 (5.0) 60 (6.8) .19 
Peripheral Venous Catheterization 0.87 (0.69, 1.09) 238 (52.2) 495 (56.2) .22 
Arterial Catheterization 1.01 (0.79, 1.30) 231 (50.7) 448 (50.9) .92 
Peritoneal Dialysis or Hemodialysis 0.68 (0.50, 0.92) 82 (18.0) 211 (24.0) .01 
Foley Catheterization 1.09 (0.85, 1.41) 159 (34.9) 292 (33.2) .50 
Intracranial Ventricular Shunt Procedure 1.78 (1.05, 3.03) 33 (7.2) 42 (4.8) .03 
Laminectomy 1.10 (0.47, 2.57) 9 (2.0) 15 (1.7) .83 
Lumbar Puncture 0.76 (0.44, 1.30) 19 (4.2) 49 (5.6) .32 
Extracorporeal Membrane Oxygenation 0.42 (0.23, 0.80) 25 (5.5) 77 (8.8) .01 
IABPb or Ventricular Assist Device Placement 0.45 (0.26, 0.78) 20 (4.4) 75 (8.5) .004 
Intravascular Stent or Catheterization 0.68 (0.50, 0.93) 83 (18.2) 210 (23.9) .02 
Trans-Esophageal Echocardiography 0.65 (0.43, 0.99) 49 (10.7) 127 (14.4) .04 
Thrombolysis 1.02 (0.76, 1.36) 87 (19.1) 166 (18.9) .92 
Blood Transfusion 0.98 (0.75, 1.29) 347 (76.1) 673 (76.5) .91 
Gastrointestinal Endoscopy 0.62 (0.45, 0.86) 64 (14.0) 176 (20.0) .003 
Tube Feedingc 1.31 (1.03, 1.67) 208 (45.6) 352 (40.0) .03 
Physical, Occupational, or Respiratory Therapy 0.78 (0.57, 1.07) 369 (80.9) 739 (84.0) .12 
Major Surgery     
          Cardiothoracic 0.70 (0.46, 1.07) 61 (13.4) 143 (16.2) .10 
          Gastrointestinal Surgery 0.64 (0.44, 0.91) 54 (11.8) 147 (16.7) .01 
          Head and Neck Surgery 1.15 (0.88, 1.51) 117 (25.7) 207 (23.5) .31 
          Neurosurgery 0.83 (0.50, 1.38) 24 (5.3) 56 (6.4) .47 
          Orthopedic Surgery 0.99 (0.65, 1.48) 51 (11.2) 100 (11.4) .94 
          Vascular Surgery 0.90 (0.64, 1.27) 57 (12.5) 122 (13.9) .54 
Total Number of Major Surgeries 0.87 (0.76, 0.99) 0.9 ± 1.0 1.00 ± 1.0 .04 
 
bContinuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BIPAP) 
cIncludes nasoenteric tube feeding and tube feeding through an esophageal, gastric, or small bowel stoma 
 
 
  13
Table 3 shows the univariate analysis of medication use. Seven variables were found to be 
significant, all protective. They included use of penicillins, cephalosporins, carbapenems, daptomycin or 
linezolid (anti-MRSA agents), rifamycin, antifungals, and PPI.  Application of topical mupirocin, which 
is used for nasal decolonization of MRSA, was not significant.  Analyzing antibiotic use in a shorter time 
period (the past 30 days as opposed to the past 6 months) resulted in a lack of significance for the anti-
MRSA antibiotics daptomycin or linezolid but did not change the significantly protective OR for the beta 
lactam classes or rifamycin (data not shown). 
 
Table 3. Univariate Analysis of Antibiotic and Other Medication Use 
Variable  Odds Ratio 
 (95% CIs) 
No. (%) of Cases
 (n=456) 
No. (%) of Controls 
 (n=880) 
p value 
Any Intravenous or Oral Antibiotic 0.70 (0.37, 1.31) 439 (96.3) 857 (97.4) .27 
Penicillin 0.69 (0.54, 0.88) 251 (55.0) 556 (63.2) .003 
Cephalosporin  0.67 (0.51, 0.88) 317 (69.5) 673 (76.5) .004 
Carbapenem 0.64 (0.44, 0.95) 42 (9.2) 114 (13.0) .03 
Fluoroquinolone 1.07 (0.84, 1.36) 154 (33.8) 284 (32.3) .60 
Macrolide 1.06 (0.80, 1.40) 104 (22.8) 191 (21.7) .70 
Glycopeptide (Vancomycin) 0.94 (0.72, 1.21) 319 (70.0) 625 (71.0) .63 
Daptomycin/Linezolid (Other Anti-MRSA Drug) 0.60 (0.40, 0.89) 39 (8.6) 116 (13.2) .01 
Aminoglycoside 0.74 (0.54, 1.02) 69 (15.1) 169 (19.2) .06 
Metronidazole 0.83 (0.65, 1.05) 219 (48.0) 461 (52.4) .12 
Sulfa (Trimethoprim-Sulfamethoxazole)  0.82 (0.60, 1.11) 81 (17.8) 178 (20.2) .20 
Rifamycin 0.34 (0.18, 0.67) 13 (2.8) 61 (6.9) .002 
Topical Mupirocin 0.78 (0.44, 1.41) 22 (5.1) 48 (5.7) .41 
Intravenous or Oral Antifungal  0.71 (0.55, 0.92) 139 (30.5) 324 (36.8) .01 
H2 Blocker 1.45 (0.99, 2.11) 409 (89.7) 761 (86.5) .05 
Proton Pump Inhibitor 0.65 (0.51, 0.83) 218 (47.8) 504 (57.3) .0005 
Vasopressor 0.95 (0.74, 1.22) 180 (39.5) 357 (40.6) 0.69 
 
Note: Antibiotic use was determined within the past 6 months.  H2 blocker and proton pump inhibitor use were determined within the 
past 30 days. Vasopressor use was determined within the past 7 days. 
3.2 MULTIVARIATE ANALYSIS   
The final multivariate analysis model included 15 independently significant variables shown in Table 4.  
Seven factors were found to be positively associated with MRSA acquisition. and included a primary 
diagnosis of respiratory disease, digestive tract disease, or injury/trauma, any diagnosis of pneumonia, 
cerebrovascular/ peripheral vascular disease, intracranial ventricular shunt procedure, and a high risk unit 
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stay prior to index culture. Eight variables were found to be protective and included history of transplant, 
extracorporeal membrane oxygenation (ECMO), intravascular stenting/catheterization, and use of two 
beta lactam antibiotic classes (penicillin and cephalosporin), rifamycin, daptomycin/linezolid, and proton 
pump inhibitors.  No interaction variables were found to be significant.  
 
Table 4. Multivariate Model for Predicting MRSA Acquisition 
Variable Odds Ratio  
(95% CIs) 
p value 
Primary Diagnosis - .0119 
          Respiratory Disease vs. Circulatory Disease 1.81 (1.14, 2.88) - 
          Digestive Tract Disease vs. Circulatory Disease 1.92 (1.12, 3.29) - 
          Injury or Trauma vs. Circulatory Disease 1.94 (1.24, 3.06) - 
          Other Diagnosis vs. Circulatory Diseasea 1.28 (0.84, 1.96) - 
Pneumonia  1.76 (1.35, 2.30) <.0001 
Cerebrovascular or Peripheral Vascular Disease 1.53 (1.10, 2.12) .0116 
Intracranial Ventricular Shunt Procedure 2.11 (1.20, 3.72) .0099 
High Risk Unit Stay Prior to Index Culture 6.24 (2.12, 18.4) .0009 
History of Transplant 0.37 (0.22, 0.62) .0001 
Extracorporeal Membrane Oxygenation 0.47 (0.23, 0.94) .0338 
Intravascular Stent or Catheterization 0.58 (0.41, 0.82) .0024 
Penicillin Use 0.62 (0.48, 0.81) .0055 
Cephalosporin Use 0.64 (0.47, 0.86) .0031 
Daptomycin/Linezolid (Other Anti-MRSA Drug) Use 0.62 (0.40, 0.96) .0306 
Rifamycin Use 0.41 (0.20, 0.83) .0133 
Proton Pump Inhibitor Use 0.70 (0.53, 0.91) .0089 
 
Note: Comorbidities were present anytime during admission. Procedures were performed within the 30 days prior to 
acquisition of MRSA. Antibiotic use was determined within the past 6 months.  Proton pump inhibitor use was 
determined within the past 30 days. 
aThis category had a CI that crossed 1.00 for but is kept in the model as part of a categorical variable. 
 
 
For the subset of cases with cultures obtained only during a high risk unit stay, the final model 
included 11 significant variables. Only two variables, admission from a long-term care facility (aOR=2.19 
(1.22, 3.92), p=.0082) and pneumonia (aOR=1.75 (1.29, 2.38), p=.0004) were associated with MRSA 
acquisition.  Protective factors similar to those in the main model and with comparable aORs and p values 
(data not shown) included admission history of transplant, ECMO, intravascular stent or cardiac 
catheterization, and use of penicillin, cephalosporin, daptomycin/linezolid, and PPI. Additional protective 
factors identified included placement of an IABP or ventricular assist device (aOR=0.41 (0.20, 0.82), 
p=.0119) and carbapenem use (aOR=0.54 (0.33, 0.88), p=.0138).   
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The final model for the subset of cases identified only by nasal surveillance culture included 13 
significant variables. Five factors were associated with MRSA acquisition and included  admission from a 
long-term care facility (aOR=1.86 (1.04, 3.32), p=.0351), pneumonia (aOR=1.68 (0.44, 0.88), p=.0027), 
presence of an intracardiac pacemaker or defibrillator (aOR=1.96 (1.10, 3.50), p=.0229), tube feeding 
(aOR=1.46 (1.04, 2.06), p=.0308), and  a high risk unit stay prior to index culture (aOR=4.62 (1.45, 14.78), 
p=.0098).  Protective factors similar to those in the main model and with comparable aORs and p values 
(data not shown) included admission history of transplant, ECMO, intravascular stent or cardiac 
catheterization, and use of penicillin, cephalosporin, daptomycin/linezolid, and PPI. An additional 
protective factor identified was abnormal albumin (aOR=0.63 (0.45, 0.89), p=.0090). 
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4.0  DISCUSSION 
4.1 EXPLANATION OF RESULTS 
4.1.1 Overall findings 
This case-control study identified several factors associated with MRSA acquisition among patients 
admitted to a high risk unit in a tertiary hospital setting, including a primary diagnosis category of 
respiratory disease, gastrointestinal disease, or trauma/injury, any diagnosis of pneumonia, 
cerebrovascular/peripheral vascular disease, exposure to a high risk unit, admission from a long-term care 
facility, intracranial ventricular shunt procedure, presence of an intracardiac pacemaker or defibrillator, 
and tube feeding. Protective factors identified that were similar across all sets of subjects analyzed 
included history of transplant, use of beta lactam antibiotics, daptomycin/linezolid, or PPI, ECMO, and 
intravascular stenting or catheterization. 
In interpreting the results of these analyses, it is important to keep in mind the population studied, 
the setting, and the method for choosing the cases and controls. The population consists mostly of 
critically ill patients since the high risk units at UPMC PUH are comprised mainly of the ICUs. The 
number of comorbid illnesses and the severity of illness of the population are reflected in the adjusted 
Charlson Comorbidity Index, the number of abnormal laboratory values, and the mortality rates, which 
were not significantly different between the case and control groups. All the patients had at least one 
invasive procedure performed, and majority was on mechanical ventilation and at least one antibiotic. 
Thus, the lack of a particular risk factor such as a comorbid illness or a prior procedure did not mean that 
the patient had no risk factors but rather that the subject was exposed to a different comorbidity or 
procedure.  The setting is also one where an intensive MRSA infection control bundle has been 
implemented and where the MRSA acquisition rates are quite low. The advantage of the study is in the 
large number of subjects and excellent medical records that could potentially identify risk factors for 
MRSA acquisition despite the baseline low MRSA acquisition rates reflective of a successful infection 
control strategy.   
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Since the cases and controls were matched by location and timing, it can be presumed that the 
two groups were exposed to similar group level antibiotic use or defined daily doses of antibiotics as well 
as a similar environment, so hospital level antibiotic use, MRSA colonization pressure, care workload, 
and unit location could not be studied as risk factors [14-15]. Since the groups were also matched by a 
minimum duration of stay, length of stay parameters would be reflective of the accuracy of the matching 
method and could not be studied as potential risk factors. Indeed, length of hospital stay, length of stay 
prior to the index culture, and lengths of stay in the high or non-high risk units were not associated with 
MRSA acquisition in this study. However, since cases potentially had their last negative nasal 
surveillance culture in a non-high risk unit and converted on their first day of admission to a high risk unit 
while some controls could have had their index culture on their first day of high risk unit admission, 
exposure to a high risk unit prior to index culture was able to be studied and found to be significantly 
different between the case and control groups. Likewise, exposure to a non-high risk unit was potentially 
different between the two groups if some subjects did not spend their entire stay in a high risk unit. The 
dichotomous variables indicating prior exposure to a high risk or non-high risk unit were thus included in 
the multivariate analysis. Since the subjects were all chosen based on cultures taken at a high risk unit, the 
resulting adjusted odds ratios (aOR) may not truly reflect the odds of exposure in a general population of 
MRSA converters to a certain type of unit.    
4.1.2 Positively associated variables 
The multivariate model identified a high risk unit stay prior to index culture as having the greatest 
association with MRSA conversion.  This should be interpreted with caution since the absolute value of 
the aOR may not reflect the true odds of being exposed to a high risk unit among cases versus controls.  
However, since the high risk units were already historically determined to have higher MRSA infection 
rates compared to other nursing units, this finding is plausible. The ICUs may have had higher MRSA 
infection rates because of potential exposure to higher organism burden of MRSA as well as performance 
of more invasive procedures during a high risk unit stay. 
Any diagnosis of pneumonia was significantly associated with MRSA acquisition in all the 
analyzed groups. This may reflect either an association with a diagnosis of pneumonia upon admission or 
association with hospital-acquired pneumonia. A diagnosis of pneumonia at any time is plausible as a risk 
factor for MRSA acquisition because of  the  decreased ability to clear secretions resulting in a favorable 
environment for MRSA to grow, damage to the respiratory tract as these conditions would promote 
adherence of MRSA, disruption of respiratory flora, and selective growth of MRSA due to antibiotic use.  
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Additionally, intubation and suctioning could serve as a portal of entry for the organism from the hands or 
equipment of the healthcare worker as could the exposure to other invasive procedures. This finding may 
be consistent with S. aureus preferring to colonize the nares and nasopharynx, which may be a source for 
aspiration and development of pneumonia. It may also reflect virulence factors in MRSA/S. aureus such 
adhesins, toxins, and phenol-soluble modulins that may be important in pneumonia pathogenesis [10, 33-
34].  
Primary diagnoses of respiratory disease, digestive tract disease, or injury/trauma diagnosis were 
associated with MRSA acquisition. This could be reflective of the underlying health status of the hosts or 
chronicity of illnesses in these diagnostic categories versus the reference category of circulatory illness or 
the mechanism of disease, such as the need for mechanical ventilation in complicated respiratory diseases.  
The types of procedures performed in patients with respiratory or gastrointestinal disease and the presence 
of open wounds in injury/trauma could increase the risk of MRSA acquisition. Among the comorbid 
illnesses (regardless of primary diagnosis), cerberovascular disease or peripheral vascular disease was 
found to be a risk factor. This variable includes patients with peripheral and cerebrovascular disease and 
so a subset also had chronic stasis ulcers and poor wound healing, which may put them at increased risk 
for MRSA acquisition. A subset of patients with cerebrovascular disease would also have undergone an 
intracranial ventricular shunt, which was the only procedure that was found to be significantly associated 
with MRSA acquisition. Ventricular shunts are often manipulated for drainage of cerebrospinal fluid 
multiple times a day, and this increased contact might explain the increased the risk of MRSA acquisition.  
Admission from a long-term care facility was significant on subset analysis. Long-term care 
residents are often elderly, have multiple comorbidities, and are debilitated. Perhaps hospitalization 
unmasks previously undetected low level colonization as MRSA colonization can occur in as much as 
62% of nursing home residents, whether nasally or extranasally, or the debilitation may contribute to 
increase risk of acquisition [35].  In addition, the presence of an intracardiac pacemaker or defibrillator 
and tube feeding was significant in the subset detected by nasal surveillance cultures only. These findings 
are consistent with conclusions from previously published studies and may be attributable to the presence 
of chronic foreign material that facilitate MRSA adhesion or manipulation and trauma of the upper 
nasopharyngeal passages which are the preferred site for colonization of S. aureus [10, 36]. The 
emergence of these risk factors in the subset analyses and not the main analysis may reflect the difference 
in the method of identification of the cases and controls in the subsets. 
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4.1.3 Negatively associated variables 
A history of transplant appeared to be protective. This may be confounded by the antibiotics that the 
transplanted patients receive as the beta lactam antibiotic classes cephalosporin, penicillin, and 
carbapenem were shown to be protective.  Of note, the transplant ICU MRSA acquisition rate per 1,000 
patient days was the lower than any other high-risk unit (Table 5).  Literature on group-level antibiotic 
use showed beta lactams to be a risk factor for MRSA colonization, which is contradictory to our 
findings, but this finding should be distinguished from being a risk factor for acquisition as opposed to 
just a finding of colonization [15-16]. Patient-level data in one study showed a trend for beta lactams 
towards being protective, which is more consistent with this study’s results [15].  In multivariate analysis, 
rifamycin, daptomycin and linezolid use were also found to be protective.  It is plausible that because 
these agents have activity against MRSA that MRSA growth on screening could have been suppressed. 
PPI were also found to be protective against MRSA acquisition, although this finding is difficult to 
explain in light of the association of PPI with the occurrence of pneumonia and other hospital-acquired 
pathogens such as C. difficile and gram positive coccal infections in a few studies [37-39]. One in vitro 
study actually investigates the potential use of PPI analogues as inhibitors of multidrug efflux 
mechanisms in S. aureus, which could point to a potential antibactericidal role [40].  
 
Table 5. Distribution of Cases by Unit for 2007-2008 in Cases per 1,000 Patient Days 
Unit Location Patient Days Total Number 
of Cases 
Cases  per 
1,000 Patient 
Days 
Medical ICU 23,385 50 2.1 
Surgical ICU 5,100 7 1.4 
Trauma ICU 15,441 35 2.3 
Transplant  ICU 18,899 21 1.1 
Neurosurgical and Neurology ICU 20,963 42                           2.0 
Cardiothoracic ICU 14,603 24 1.6 
Coronary Care Unit 7,008 15 2.1 
Orthopedic Unit 11,454 21 1.8 
 
 
Cardiology procedures such as extracorporeal membrane oxygenation, cardiac catheterization and 
stenting, the placement of an IABP or ventricular assist device, were found to be protective in all the 
multivariate models. The trend throughout the study’s results indicates that there were more 
cardiovascular procedures or diagnoses among the controls.  This finding may be reflective of the 
underlying good health status of subjects who undergo some of these procedures, as they are often only 
performed in patients who receive medical clearance or in those with an acute onset cardiovascular event. 
Of note, no interaction or association with mupirocin, which is often used for nasal decolonization, or 
other antibiotics were noted.    
4.1.4 Variables not associated with MRSA acquisition 
There was no association between isolation precautions for other organisms and MRSA acquisition. 
Contact precautions are designed to prevent transmission from the isolated case to others, not from others 
to the individual and so barrier use in cases would not be expected to be protected.  No interaction 
variables were found to be significant. Certain patient-associated risk factors identified in previous studies 
were not found to be significant in this study, such as tracheostomy, skin ulcers, and fluoroquinolones, 
although the unadjusted mORs for these variables trended towards an association with MRSA acquisition. 
The smaller subsets analyzed showed some similarities in  results to the larger dataset, although  the 
smaller sample size in these subsets may explain the lack of significant association found in some of the 
variables in the original final model.  
 
4.2 LIMITATIONS 
One limitation of the study is that data was retrospective and only captured via electronic extraction. 
Therefore, certain conditions, such as skin ulcers, may have been missed if they were not coded into ICD9 
codes. Another limitation is that there may not always be culture confirmation of MRSA acquisition if 
cultures were not ordered on patients or if cultures were done at another laboratory. Completeness of 
individual subject data depended on the available electronic and paper records. Sensitivity of detection of 
MRSA also depended on the sensitivity of the culture methods. However, these potential biases would 
unlikely be different for the groups.  Due to multiple comparisons among many variables, the p value of 
<0.05 may be overly sensitive to detect potential risk factors for MRSA acquisition but was felt to be 
appropriate due to the exploratory nature of the study.  Because of the study design, residual confounding 
may have occurred.  In addition, causation cannot be determined in an observational study.  
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5.0  CLINICAL SIGNIFICANCE AND CONCLUSION 
The final model included 15 independently significant variables. Seven factors were found to be 
positively associated with MRSA acquisition. They included a primary diagnosis of respiratory disease 
digestive tract disease, or injury/trauma, any diagnosis of pneumonia, cerebrovascular/ peripheral vascular 
disease, intracranial ventricular shunt procedure, and a high risk unit stay prior to index culture. As 3 of 
the 7 factors that were positively associated with MRSA acquisition were primary diagnoses present on 
admission, they were not modifiable. Of the remaining 4, pneumonia, specifically pneumococcal 
pneumonia, could potentially be reduced by maintaining high compliance with pneumococcal vaccine 
immunization but this too would likely need to occur prior to admission.  The other conditions found to 
be associated with MRSA acquisition could potentially be targeted for more intensive surveillance in 
hopes of identifying (and isolating) acquisition sooner. Admission to a high risk unit in itself is not 
modifiable.  
Eight variables were found to be protective and included two beta lactam antibiotic classes 
(penicillin and cephalosporin), rifamycin, daptomycin/ linezolid, proton pump inhibitors, history of 
transplant, extracorporeal membrane oxygenation (ECMO), and intravascular stenting/catheterization.   
Overall, there was a remarkable paucity of significance of many of the major surgeries and 
procedures studied as risk factors for MRSA acquisition.  This argues for the importance of the rigorous 
application of routine infection control infection control strategies such as hand hygiene before and after 
patient and or environmental contact, habitual cleaning of equipment, as well as assiduous use of and 
removal of barriers as appropriate. Additionally, the use of the MRSA prevention bundle may have 
helped to safeguard patients undergoing procedures, who might not have otherwise been protected, as this 
program identifies colonized patients and requires implementation of barrier precautions.  
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